Clinical trials
Angioimmunoblastic T-cell Lymphoma clinical trials
Below are recruiting angioimmunoblastic t-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 52 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
New Haven, ConnecticutAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Little Rock, ArkansasAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Birmingham, AlabamaAges 18–75 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05572983RecruitingPhase 2
New treatment for a specific T-cell lymphoma type
This Phase 2 trial tests chidamide plus CHOP chemotherapy in people who have not received any prior treatment for a certain type of peripheral T-cell lymphoma. The study aims to shrink the lymphoma and improve outcomes while checking for side effects and safety.
Guangzhou, GuangdongAges 18–75 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07168317RecruitingPhase 2
Study of tislelizumab plus other drugs for new AITL lymphoma
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
Xuzhou, JiangsuAges 18 years+ - NCT07058103RecruitingPhase 2
Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Xuzhou, JiangsuAges 18 years+ - NCT07293403RecruitingPhase 2
Duvelisib maintenance for peripheral T-cell lymphoma
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Birmingham, AlabamaAges 1–31 - NCT03964480Recruiting
Registry for newly diagnosed peripheral T-cell lymphoma patients
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Stanford, CaliforniaAges 18 years+ - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Scottsdale, ArizonaAges 18 years+ - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75 - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT05230680RecruitingPhase 1/Phase 2
Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
SeoulAges 20–85 - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT05949944RecruitingPhase 1/Phase 2
Testing linperlisib plus CHOP for untreated peripheral T-cell lymphoma
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
Guangzhou, GuangdongAges 18 years+ - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99
Hear when a new Angioimmunoblastic T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Angioimmunoblastic T-cell Lymphoma trials by city
Studies with a site in or near these metro areas.
Angioimmunoblastic T-cell Lymphoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for angioimmunoblastic t-cell lymphoma?
- Yes. Clin2 currently lists 52 recruiting angioimmunoblastic t-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a angioimmunoblastic t-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a angioimmunoblastic t-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.